When.com Web Search

  1. Ads

    related to: qelbree fda approval date epclusa 5 0 2

Search results

  1. Results From The WOW.Com Content Network
  2. Viloxazine - Wikipedia

    en.wikipedia.org/wiki/Viloxazine

    [6] [1] [5] The immediate-release form has an elimination half-life of 2.5 hours [6] [2] while the half-life of the extended-release form is 7 hours. [1] Viloxazine was first described by 1972 [10] and was marketed as an antidepressant in Europe in 1974. [6] [11] It was not marketed in the United States at this time. [12]

  3. Sofosbuvir/velpatasvir - Wikipedia

    en.wikipedia.org/wiki/Sofosbuvir/velpatasvir

    Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]

  4. List of investigational attention deficit hyperactivity ...

    en.wikipedia.org/wiki/List_of_investigational...

    Pirepemat (IRL-752) – "cortical enhancer" / serotonin 5-HT 7 receptor antagonist and α 2C-adrenergic receptor antagonist, other actions [96] [97] Pozanicline (A-87089.0, ABT-089) – α 4 β 2 nicotinic acetylcholine receptor agonist [98] SEP-225432 – serotonin–norepinephrine–dopamine reuptake inhibitor [99]

  5. Management of attention deficit hyperactivity disorder

    en.wikipedia.org/wiki/Management_of_attention...

    Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...

  6. Velpatasvir - Wikipedia

    en.wikipedia.org/wiki/Velpatasvir

    Plasma protein binding is over 99.5%. It is slowly metabolised by the liver enzymes CYP2B6, CYP2C8 and CYP3A4. While monohydroxylated and demethylated metabolites have been identified in human blood plasma and faeces, over 98% of the circulating substance is velpatasvir itself. [4] 94% are excreted via the faeces, and only 0.4% via the urine. [1]

  7. FDA approves new type of schizophrenia drug - AOL

    www.aol.com/news/fda-approves-type-schizophrenia...

    The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

  1. Ads

    related to: qelbree fda approval date epclusa 5 0 2